NEW YORK (GenomeWeb) — Cancer Genetics said this week that it has signed a non-exclusive supply agreement with Agilent Technologies for probe reagents for its FISH-based HPV-Associated Cancer Test (FHACT).
CGI's test — a laboratory developed assay under CLIA in the US that also has CE marking — assesses genomic changes often found in cervical cancers to help identify patients who are at higher risk for disease progression.
Under the terms of the deal, Agilent will manufacture custom probes for CGI for use in the test. Rutherford, New Jersey-based CGI said it also intends to outlicense the probes through domestic and international distribution channels, with licensors able to purchase Agilent-manufactured probes.
Additional terms were not disclosed.
"This agreement marks an important milestone for Cancer Genetics and the company's FHACT test as it allows for expansion of our international business opportunities by outlicensing our probes, which is an integral part of the company's new strategy for revenue generation and path to profitability," CGI CEO John Roberts said in a statement.